Top Page
Alpha Tau Medical Ltd
(NASDAQ:DRTS)
Alpha Tau Medical Ltd (DRTS) vs. SPDR S&P 500 ETF (SPY)
Alpha Tau Medical Ltd Business Overview & Revenue Model
Alpha Tau Medical Ltd Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.23M | -1.10M | -1.07M | -979.00K | -776.00K |
| EBITDA | -41.06M | -30.30M | -28.03M | -32.74M | -13.21M |
| Net Income | -42.63M | -31.75M | -29.16M | -33.76M | -27.27M |
Balance Sheet | |||||
| Total Assets | 106.58M | 86.20M | 107.39M | 120.15M | 42.22M |
| Cash, Cash Equivalents and Short-Term Investments | 76.90M | 59.60M | 81.79M | 104.53M | 31.32M |
| Total Debt | 13.73M | 12.54M | 13.28M | 5.19M | 53.96M |
| Total Liabilities | 29.48M | 23.54M | 22.91M | 14.49M | 76.99M |
| Stockholders Equity | 77.10M | 62.67M | 84.47M | 105.66M | -34.78M |
Cash Flow | |||||
| Free Cash Flow | -32.76M | -22.02M | -24.36M | -24.78M | -14.74M |
| Operating Cash Flow | -26.68M | -19.78M | -17.96M | -23.88M | -11.81M |
| Investing Cash Flow | -20.59M | 20.77M | 18.68M | -89.94M | 19.27M |
| Financing Cash Flow | 45.77M | 25.00K | 5.30M | 96.91M | 111.00K |
Alpha Tau Medical Ltd Technical Analysis
Alpha Tau Medical Ltd Risk Analysis
Alpha Tau Medical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $1.66B | -11.68 | -90.96% | ― | -52.08% | -69.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $638.07M | -8.74 | -57.29% | ― | ― | -22.82% | |
49 Neutral | $412.60M | -13.08 | -38.92% | ― | ― | 80.95% | |
46 Neutral | $479.53M | -4.99 | -90.49% | ― | ― | 4.97% | |
45 Neutral | $464.60M | -1.33 | -91.83% | ― | ― | -67.41% | |
42 Neutral | $428.01M | -3.90 | -69.67% | ― | ― | -11.41% |
Alpha Tau Medical Ltd Corporate Events
Alpha Tau Medical Ltd., the developer of the Alpha DaRT alpha-radiation cancer therapy, reported its full-year 2025 results on March 9, 2026, alongside a broad clinical and regulatory update. The company is expanding into major cancer indications such as pancreatic, prostate, and brain tumors, while scaling manufacturing at its New Hampshire facility to support anticipated commercial demand.
In recent months, Alpha Tau secured Japanese marketing approval for Alpha DaRT in unresectable locally advanced or recurrent head and neck cancer, its first approval outside Israel, and obtained FDA approval to launch a U.S. pilot trial in locally recurrent prostate cancer. It also treated the first patient in a U.S. recurrent glioblastoma trial, submitted the first module of a U.S. PMA for recurrent cutaneous squamous cell carcinoma, and reported encouraging pancreatic cancer data at the ASCO GI Symposium.
Looking ahead, the company targets completion of patient recruitment in its pivotal U.S. ReSTART skin cancer trial by the end of Q1 2026, its U.S. pancreatic cancer pilot study in Q2 2026, and its recurrent glioblastoma feasibility trial in the second half of 2026. These milestones, coupled with post-marketing surveillance obligations in Japan, are set to shape Alpha Tau’s regulatory and commercial trajectory across multiple high-need oncology markets.
Financially, Alpha Tau’s R&D expenses rose to $32.1 million in 2025 from $27.0 million in 2024, and G&A costs also increased, driving a wider net loss of $42.6 million, or $0.53 per share, versus a $31.8 million loss a year earlier. Despite the higher burn, the company ended 2025 with $76.9 million in cash, cash equivalents, and deposits, up from $62.9 million, supporting ongoing clinical development and pre-commercial activities.
The most recent analyst rating on (DRTS) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On February 24, 2026, Alpha Tau Medical Ltd. announced that Japan’s Ministry of Health, Labour and Welfare granted Shonin marketing approval for its Alpha DaRT therapy to treat unresectable locally advanced or locally recurrent head and neck cancer. The decision follows rigorous review by Japan’s Pharmaceuticals and Medical Devices Agency and marks the first approval of Alpha DaRT outside Israel, signaling regulatory validation of this first-in-kind intratumoral alpha-radiation platform.
As a condition of approval, Alpha Tau will conduct a post‑market surveillance study of 66 patients at five leading Japanese centers to further assess safety and performance in real-world practice. Backed by longstanding collaboration with distributor HekaBio and strong support from Japanese medical societies and clinicians, the early Japanese authorization—preceding similar decisions in the U.S. and Europe—could enhance Alpha Tau’s standing in global oncology and accelerate clinical adoption in head and neck cancer.
The most recent analyst rating on (DRTS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On January 29, 2026, Alpha Tau Medical issued a shareholder letter outlining an intensifying clinical and pre-commercial agenda for 2026, highlighted by five concurrent U.S. trials of its Alpha DaRT therapy in skin, pancreatic, brain and prostate cancers, additional studies in Europe and Israel, and preparations for a large basket trial in the UK. The company expects to complete patient recruitment in its IMPACT pancreatic cancer trial by the end of the first quarter of 2026 with initial data anticipated by year-end, is targeting first results from its U.S. glioblastoma study around the end of 2026, and is awaiting a near-term regulatory decision in Japan on Alpha DaRT for recurrent head and neck cancer that could mark its first commercial approval outside Israel. Alongside ongoing data generation from its pivotal ReSTART skin cancer trial and planned exploration of Alpha DaRT in combination with checkpoint inhibitors for advanced head and neck cancer, Alpha Tau is ramping U.S. manufacturing capacity, advancing a modular PMA submission to the FDA, and building organizational and production infrastructure in the U.S. and Israel, signaling that it is positioning itself for potential commercialization and broader adoption of its platform if upcoming clinical and regulatory milestones are favorable.
The most recent analyst rating on (DRTS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On January 6, 2026, Alpha Tau Medical reported final results from its first-in-human pancreatic ductal adenocarcinoma study in Montreal, showing an 81% disease control rate across 32 patients treated with its Alpha DaRT therapy, rising to 87% when excluding the first two low-dose feasibility patients, along with a 22–23% objective response rate and a favorable safety profile. Complementary data from 23 patients demonstrated preservation of key immune and inflammatory markers one month after treatment, including stable neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and a marked reduction in IL-6 levels, suggesting an immune-preserving, less inflammatory radiation profile that could support combination with systemic therapies such as chemotherapy or immunotherapy; these findings reinforce Alpha Tau’s strategic focus on pancreatic cancer, underpin ongoing U.S. and European trials, and may strengthen the company’s positioning as it seeks future regulatory approval for Alpha DaRT in this high-need indication.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On January 5, 2026, Alpha Tau Medical announced it has submitted the first module of its pre-market approval application to the U.S. Food and Drug Administration for Alpha DaRT in the treatment of recurrent cutaneous squamous cell carcinoma in patients who are not candidates for surgery or standard radiation and lack curative systemic options. The FDA has allowed the company to use a modular PMA approach, enabling staged review of non-clinical and other data, and the initial module focuses on comprehensive non-clinical documentation; this step, taken in parallel with the ongoing multi-center ReSTART pivotal study that is expected to complete patient recruitment in the first quarter of 2026, marks a key regulatory milestone that could help streamline U.S. review and potentially strengthen Alpha Tau’s position in the skin cancer treatment market if future modules and clinical results support approval.
The most recent analyst rating on (DRTS) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On December 18, 2025, Alpha Tau Medical Ltd. announced that CEO Uzi Sofer and CFO Raphi Levy will deliver a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026, and will hold one-on-one meetings with institutional investors during the event. The presentation is expected to highlight the company’s recent achievements and outline upcoming data milestones for its Alpha DaRT solid-tumor therapy, signaling an effort to raise Alpha Tau’s visibility with global healthcare investors and potentially strengthen its position within the oncology therapeutics space as it advances toward further clinical and commercial development.
The most recent analyst rating on (DRTS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.